يعرض 1 - 20 نتائج من 57 نتيجة بحث عن '"Rukazenkov, Yuri"', وقت الاستعلام: 0.55s تنقيح النتائج
  1. 1
    Academic Journal
    Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer

    المؤلفون: Johnson, Martin, Lin, Yu‐Wei, Schmidt, Henning, Sunnaker, Mikael, Van Maanen, Eline, Huang, Xiangning, Rukazenkov, Yuri, Tomkinson, Helen, Vishwanathan, Karthick

    المساهمون: AstraZeneca

    المصدر: British Journal of Clinical Pharmacology ; ISSN 0306-5251 1365-2125

    الاتاحة: http://dx.doi.org/10.1111/bcp.16199
    https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.16199

    View record in BASE

    أضف إلى المفضلة
  2. 2
    Academic Journal
    Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

    المؤلفون: Tsuboi, Masahiro, Herbst, Roy S., John, Thomas, Kato, Terufumi, Majem, Margarita, Grohé, Christian, Wang, Jie, Goldman, Jonathan W., Lu, Shun, de Marinis, Filippo, Shepherd, Frances A., Lee, Ki Hyeong, Le, Nhieu Thi, Dechaphunkul, Arunee, Kowalski, Dariusz, Bonanno, Laura, Dómine, Manuel, Poole, Lynne, Bolanos, Ana, Rukazenkov, Yuri, Wu, Yi-Long

    المساهمون: AstraZeneca

    المصدر: Targeted Oncology ; volume 19, issue 2, page 131-134 ; ISSN 1776-2596 1776-260X

    الاتاحة: http://dx.doi.org/10.1007/s11523-024-01034-3
    https://link.springer.com/content/pdf/10.1007/s11523-024-01034-3.pdf
    https://link.springer.com/article/10.1007/s11523-024-01034-3/fulltext.html

    View record in BASE

    أضف إلى المفضلة
  3. 3
    Academic Journal
    Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

    المؤلفون: Chmielecki, Juliann, Gray, Jhanelle E., Cheng, Ying, Ohe, Yuichiro, Imamura, Fumio, Cho, Byoung Chul, Lin, Meng-Chih, Majem, Margarita, Shah, Riyaz, Rukazenkov, Yuri, Todd, Alexander, Markovets, Aleksandra, Barrett, J. Carl, Hartmaier, Ryan J., Ramalingam, Suresh S.

    المساهمون: AstraZeneca

    المصدر: Nature Communications ; volume 14, issue 1 ; ISSN 2041-1723

    الاتاحة: http://dx.doi.org/10.1038/s41467-023-35961-y
    https://www.nature.com/articles/s41467-023-35961-y.pdf
    https://www.nature.com/articles/s41467-023-35961-y

    View record in BASE

    أضف إلى المفضلة
  4. 4
    Academic Journal
    Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

    المؤلفون: Chmielecki, Juliann, Gray, Jhanelle E., Cheng, Ying, Ohe, Yuichiro, Imamura, Fumio, Cho, Byoung Chul, Lin, Meng-Chih, Majem, Margarita, Shah, Riyaz, Rukazenkov, Yuri, Todd, Alexander, Markovets, Aleksandra, Barrett, J. Carl, Hartmaier, Ryan J., Ramalingam, Suresh S.

    المصدر: Nature Communications ; volume 14, issue 1 ; ISSN 2041-1723

    الاتاحة: https://doi.org/10.1038/s41467-023-38999-0
    https://www.nature.com/articles/s41467-023-38999-0.pdf
    https://www.nature.com/articles/s41467-023-38999-0

    View record in BASE

    أضف إلى المفضلة
  5. 5
    Academic Journal
    Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3.

    المؤلفون: Gray, Jhanelle E., Markovets, Aleksandra, Reungwetwattana, Thanyanan, Majem, Margarita, Nogami, Naoyuki, Peled, Nir, Lee, Jong-Seok, Cho, Byoung Chul, Chewaskulyong, Busayamas, John, Tom, Han, Ji-Youn, Sebastian, Martin, Todd, Alexander, Rukazenkov, Yuri, Barrett, Carl, Chmielecki, Juliann, Lee, Siow Ming, Ramalingam, Suresh S., Hartmaier, Ryan

    المصدر: Journal of Thoracic Oncology; Nov2024, Vol. 19 Issue 11, p1525-1538, 14p


    أضف إلى المفضلة
  6. 6
    Periodical
    Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFRMutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3

    المؤلفون: Gray, Jhanelle E., Markovets, Aleksandra, Reungwetwattana, Thanyanan, Majem, Margarita, Nogami, Naoyuki, Peled, Nir, Lee, Jong-Seok, Cho, Byoung Chul, Chewaskulyong, Busayamas, John, Tom, Han, Ji-Youn, Sebastian, Martin, Todd, Alexander, Rukazenkov, Yuri, Barrett, Carl, Chmielecki, Juliann, Lee, Siow Ming, Ramalingam, Suresh S., Hartmaier, Ryan

    المصدر: Journal of Thoracic Oncology; November 2024, Vol. 19 Issue: 11 p1525-1538, 14p


    أضف إلى المفضلة
  7. 7
    Academic Journal
    Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic

    المؤلفون: Gray, Jhanelle E., Han, Ji-Youn, Telaranta-Keerie, Aino, Huang, Xiangning, Kohlmann, Alexander, Hodge, Rachel, Rukazenkov, Yuri, Chmielecki, Juliann, Espenschied, Carin R., Lefterova, Martina, Wu, Yi-Long, Ramalingam, Suresh S., Barrett, J. Carl, Odegaard, Justin I.

    المساهمون: AstraZeneca

    المصدر: The Journal of Molecular Diagnostics ; volume 26, issue 1, page 73-84 ; ISSN 1525-1578

    الاتاحة: http://dx.doi.org/10.1016/j.jmoldx.2023.10.002
    https://api.elsevier.com/content/article/PII:S1525157823002647?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1525157823002647?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  8. 8
    Academic Journal
    A plain language summary of results from the ADAURA study : osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer

    المؤلفون: Wu, Yi-Long, Tsuboi, Masahiro, John, Thomas, Grohe, Christian, Majem, Margarita, Goldman, Jonathan W., Laktionov, Konstantin, Kim, Sang-We, Kato, Terufumi, Vu, Huu Vinh, Lu, Shun, Lee, Kye-Young, Akewanlop, Charuwan, Yu, Chong-Jen, De Marinis, Filippo, Bonanno, Laura, Dómine Gómez, Manuel, Shepherd, Frances A, Zeng, Lingmin, Hodge, Rachel, Atasoy, Ajlan, Rukazenkov, Yuri, Herbst, Roy S

    وصف الملف: application/pdf

    Relation: Future oncology (London, England); Vol. 17 Núm. 35 (december 2021), p. 4827-4835; https://ddd.uab.cat/record/270250; urn:oai:ddd.uab.cat:270250; urn:scopus_id:85120636168; urn:pmid:34723634; urn:articleid:17448301v17n35p4827

    الاتاحة: https://ddd.uab.cat/record/270250

    View record in BASE Full Text Finder

    أضف إلى المفضلة
  9. 9
    Academic Journal
    Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC

    المؤلفون: Ramalingam, Suresh S, Vansteenkiste, Johan, Planchard, David, Cho, Byoung Chul, Gray, Jhanelle E, Ohe, Yuichiro, Zhou, Caicun, Reungwetwattana, Thanyanan, Cheng, Ying, Chewaskulyong, Busyamas, Shah, Riyaz, Cobo, Manuel, Lee, Ki Hyeong, Cheema, Parneet, Tiseo, Marcello, John, Thomas, Lin, Meng-Chih, Imamura, Fumio, Kurata, Takayasu, Todd, Alexander, Hodge, Rachel, Saggese, Matilde, Rukazenkov, Yuri, Soria, Jean-Charles, FLAURA Investigators

    المصدر: Ramalingam, Suresh S; Vansteenkiste, Johan; Planchard, David; Cho, Byoung Chul; Gray, Jhanelle E; Ohe, Yuichiro; Zhou, Caicun; Reungwetwattana, Thanyanan; Cheng, Ying; Chewaskulyong, Busyamas; Shah, Riyaz; Cobo, Manuel; Lee, Ki Hyeong; Cheema, Parneet; Tiseo, Marcello; John, Thomas; Lin, Meng-Chih; Imamura, Fumio; Kurata, Takayasu; Todd, Alexander; Hodge, Rachel; Saggese, Matilde; Rukazenkov, Yuri; Soria, Jean-Charles; FLAURA Investigators (2020). Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. New England Journal of Medicine, 382(1):41-50.

    مصطلحات موضوعية: Clinic for Oncology and Hematology, 610 Medicine & health

    وصف الملف: application/pdf

    Relation: https://www.zora.uzh.ch/id/eprint/184641/1/ZORA184641.pdf; info:pmid/31751012; urn:issn:0028-4793

    الاتاحة: https://www.zora.uzh.ch/id/eprint/184641/
    https://www.zora.uzh.ch/id/eprint/184641/1/ZORA184641.pdf
    https://doi.org/10.1056/NEJMoa1913662

    View record in BASE

    أضف إلى المفضلة
  10. 10
    Academic Journal
    Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

    المؤلفون: Gray, Jhanelle E, Okamoto, Isamu, Sriuranpong, Virote, Vansteenkiste, Johan, Imamura, Fumio, Lee, Jong Seok, Pang, Yong-Kek, Cobo, Manuel, Kasahara, Kazuo, Cheng, Ying, Nogami, Naoyuki, Cho, Eun Kyung, Su, Wu Chou, Zhang, Guili, Huang, Xiangning, Li-Sucholeiki, Xiaocheng, Lentrichia, Brian, Dearden, Simon, Jenkins, Suzanne, Saggese, Matilde, Rukazenkov, Yuri, Ramalingam, Suresh S

    مصطلحات موضوعية: Acrylamides, Alleles, Amino Acid Substitution, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Clinical Decision-Making, Clinical Trials, Phase III as Topic, Disease Management, ErbB Receptors, Female, Humans, Lung Neoplasms, Male, Mutation, Neoplasm Metastasis, Neoplasm Staging, Protein Kinase Inhibitors, Randomized Controlled Trials as Topic, Treatment Outcome

    Relation: http://hdl.handle.net/10668/14431; PMC7209579; https://lirias.kuleuven.be/bitstream/123456789/641233/2/1078-0432.CCR-19-1126.full.pdf; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209579/pdf

    الاتاحة: http://hdl.handle.net/10668/14431
    https://doi.org/10.1158/1078-0432.CCR-19-1126
    https://lirias.kuleuven.be/bitstream/123456789/641233/2/1078-0432.CCR-19-1126.full.pdf
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209579/pdf

    View record in BASE Full Text Finder

    أضف إلى المفضلة
  11. 11
    Academic Journal
    Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer

    المؤلفون: Planchard, David, Boyer, Michael J., Lee, Jong-Seok, Dechaphunkul, Arunee, Cheema, Parneet K., Takahashi, Toshiaki, Gray, Jhanelle E., Tiseo, Marcello, Ramalingam, Suresh S., Todd, Alexander, McKeown, Astrid, Rukazenkov, Yuri, Ohe, Yuichiro

    مصطلحات موضوعية: Cancer Research, Oncology

    Relation: url:https://www.openaccessrepository.it/communities/itmirror; https://www.openaccessrepository.it/record/170294

    الاتاحة: https://www.openaccessrepository.it/record/170294
    https://doi.org/10.1158/1078-0432.ccr-18-3325

    View record in BASE

    أضف إلى المفضلة
  12. 12
    Academic Journal
    Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer

    المؤلفون: Soria, Jean-Charles, Ohe, Yuichiro, Vansteenkiste, Johan, Reungwetwattana, Thanyanan, Chewaskulyong, Busyamas, Lee, Ki Hyeong, Dechaphunkul, Arunee, Imamura, Fumio, Nogami, Naoyuki, Kurata, Takayasu, Okamoto, Isamu, Zhou, Caicun, Cho, Byoung Chul, Cheng, Ying, Cho, Eun Kyung, Voon, Pei Jye, Planchard, David, Su, Wu-Chou, Gray, Jhanelle E, Lee, Siow-Ming, Hodge, Rachel, Marotti, Marcelo, Rukazenkov, Yuri, Ramalingam, Suresh S, FLAURA Investigators

    المصدر: Soria, Jean-Charles; Ohe, Yuichiro; Vansteenkiste, Johan; Reungwetwattana, Thanyanan; Chewaskulyong, Busyamas; Lee, Ki Hyeong; Dechaphunkul, Arunee; Imamura, Fumio; Nogami, Naoyuki; Kurata, Takayasu; Okamoto, Isamu; Zhou, Caicun; Cho, Byoung Chul; Cheng, Ying; Cho, Eun Kyung; Voon, Pei Jye; Planchard, David; Su, Wu-Chou; Gray, Jhanelle E; Lee, Siow-Ming; Hodge, Rachel; Marotti, Marcelo; Rukazenkov, Yuri; Ramalingam, Suresh S; FLAURA Investigators (2018). Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. New England Journal of Medicine, 378(2):113-125.

    مصطلحات موضوعية: Clinic for Oncology and Hematology, 610 Medicine & health

    وصف الملف: application/pdf

    Relation: https://www.zora.uzh.ch/id/eprint/149579/1/ZORA149579.pdf; info:pmid/29151359; urn:issn:0028-4793

    الاتاحة: https://www.zora.uzh.ch/id/eprint/149579/
    https://www.zora.uzh.ch/id/eprint/149579/1/ZORA149579.pdf
    https://doi.org/10.1056/NEJMoa1713137

    View record in BASE

    أضف إلى المفضلة
  13. 13
    Academic Journal
    Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer

    المؤلفون: Ramalingam, Suresh S., Yang, James C. -H., Lee, Chee Khoon, Kurata, Takayasu, Kim, Dong-Wan, John, Thomas, Nogami, Naoyuki, Ohe, Yuichiro, Mann, Helen, Rukazenkov, Yuri, Ghiorghiu, Serban, Stetson, Daniel, Markovets, Aleksandra, Barrett, J. Carl, Thress, Kenneth S., Janne, Pasi A.

    المساهمون: 김동완, Kim, Dong-Wan

    Relation: Journal of Clinical Oncology, Vol.36 No.9, pp.841-849; 74825; http://hdl.handle.net/10371/165224; 2-s2.0-85032451704; 000429062700003

    الاتاحة: http://hdl.handle.net/10371/165224
    https://doi.org/10.1200/JCO.2017.74.7576
    https://ascopubs.org/doi/10.1200/JCO.2017.74.7576

    View record in BASE

    أضف إلى المفضلة
  14. 14
    Academic Journal
    CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

    المؤلفون: Reungwetwattana, Thanyanan, Nakagawa, Kazuhiko, Cho, Byoung Chul, Cobo, Manuel, Cho, Eun Kyung, Bertolini, Alessandro, Bohnet, Sabine, Zhou, Caicun, Lee, Ki Hyeong, Nogami, Naoyuki, Okamoto, Isamu, Leighl, Natasha, Hodge, Rachel, McKeown, Astrid, Brown, Andrew P, Rukazenkov, Yuri, Ramalingam, Suresh S, Vansteenkiste, Johan

    Relation: http://hdl.handle.net/10668/12878; https://lirias.kuleuven.be/bitstream/123456789/628382/2/jco.2018.78.3118.pdf

    الاتاحة: http://hdl.handle.net/10668/12878
    https://doi.org/10.1200/JCO.2018.78.3118
    https://lirias.kuleuven.be/bitstream/123456789/628382/2/jco.2018.78.3118.pdf

    View record in BASE

    أضف إلى المفضلة
  15. 15
    Academic Journal
    ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

    المؤلفون: Wu, Yi-Long, Herbst, Roy S., Mann, Helen, Rukazenkov, Yuri, Marotti, Marcelo, Tsuboi, Masahiro

    المصدر: Clinical Lung Cancer ; volume 19, issue 4, page e533-e536 ; ISSN 1525-7304

    الاتاحة: http://dx.doi.org/10.1016/j.cllc.2018.04.004
    https://api.elsevier.com/content/article/PII:S152573041830086X?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S152573041830086X?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  16. 16
    Periodical
    Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFRMutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in VitroDiagnostic

    المؤلفون: Gray, Jhanelle E., Han, Ji-Youn, Telaranta-Keerie, Aino, Huang, Xiangning, Kohlmann, Alexander, Hodge, Rachel, Rukazenkov, Yuri, Chmielecki, Juliann, Espenschied, Carin R., Lefterova, Martina, Wu, Yi-Long, Ramalingam, Suresh S., Barrett, J. Carl, Odegaard, Justin I.

    المصدر: The Journal of Molecular Diagnostics; January 2024, Vol. 26 Issue: 1 p73-84, 12p

    Full Text Finder

    أضف إلى المفضلة
  17. 17
    Academic Journal
    Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

    المؤلفون: Wu, Yi-Long, Saijo, Nagahiro, Thongprasert, Sumitra, Yang, J. C.-H., Han, Baohui, Margono, Benjamin, Chewaskulyong, Busayamas, Sunpaweravong, Patrapim, Ohe, Yuichiro, Ichinose, Yukito, Yang, Jin-Ji, Mok, Tony S.K., Young, Helen, Haddad, Vincent, Rukazenkov, Yuri, Fukuoka, Masahiro

    المساهمون: AstraZeneca. IRESSA

    المصدر: Lung Cancer ; volume 104, page 119-125 ; ISSN 0169-5002

    الاتاحة: http://dx.doi.org/10.1016/j.lungcan.2016.11.022
    https://api.elsevier.com/content/article/PII:S0169500216305384?httpAccept=text/plain
    https://api.elsevier.com/content/article/PII:S0169500216305384?httpAccept=text/xml

    View record in BASE

    أضف إلى المفضلة
  18. 18
    Conference
    Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg

    المؤلفون: DI LEO, Angelo, JERUSALEM, Guy, PETRUZELKA, Lubos, TORRES, Roberto, BONDARENKO, Igor N., KHASANOV, Rustem, VERHOEVEN, Didier, PEDRINI, José L., SMIRNOVA, Iva, LICHINITSER, Mikhail R., PENDERGRASS, Kelly, GARNETT, Sally, RUKAZENKOV, Yuri, MARTIN, Miguel

    المصدر: Cancer Research. Supplement, 72 (24), S1-4 (2012-12-15); San Antonio Breast Cancer Symposium, San Antonio, United States [US], 4-8 December, 2012

    مصطلحات موضوعية: Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

    Relation: urn:issn:0576-6656

    URL الوصول: https://orbi.uliege.be/handle/2268/156154

    View record in ORBi

    أضف إلى المفضلة
  19. 19
    Academic Journal
    Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

    المؤلفون: Robertson, John, Ellis, Matthew, Llombart-Cussac, Antonio, Feltl, David, Dewar, John, Jasi�wka, Marek, Hewson, Nicola, Rukazenkov, Yuri

    Relation: https://nottingham-repository.worktribe.com/output/1118300; Journal of Clinical Oncology; Volume 33; Issue 32; Pagination 3781-3787

    الاتاحة: https://doi.org/10.1200/JCO.2015.61.5831
    https://nottingham-repository.worktribe.com/file/1118300/1/jco.2015.61.5831
    https://nottingham-repository.worktribe.com/output/1118300

    View record in BASE

    أضف إلى المفضلة
  20. 20
    Academic Journal
    Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial.

    المؤلفون: Leo, Angelo Di, Jerusalem, Guy, Petruzelka, Lubos, Torres, Roberto, Bondarenko, Igor N., Khasanov, Rustem, Verhoeven, Didier, Pedrini, Jose L., Smirnova, Iya, Lichinitser, Mikhail R., Pendergrass, Kelly, Malorni, Luca, Garnett, Sally, Rukazenkov, Yuri, Martin, Miguel

    المصدر: Journal of the National Cancer Institute, 106 (1), djt337 (2014)

    مصطلحات موضوعية: Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

    Relation: urn:issn:0027-8874; urn:issn:1460-2105; https://orbi.uliege.be/handle/2268/162270; info:hdl:2268/162270; info:pmid:24317176

    الاتاحة: https://orbi.uliege.be/handle/2268/162270
    https://orbi.uliege.be/bitstream/2268/162270/1/Final%20overall%20survival%20-%20Fulvestrant%20500%20mg%20vs%20250%20mg%20in%20the%20randomized%20CONFIRM%20trial.pdf
    https://doi.org/10.1093/jnci/djt337

    View record in BASE Full Text Finder

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء